Search:

Merger and Acquisition

When companies plan to enhance its product line for future, penetrate to broad markets, achieve leadership market status in specific therapeutic areas, M & A is one of the key strategic options to establish or enhance their operation in China with high efficiency, cost savings, and competitive market access capabilities.

With its marketing research team, and comprehensive data warehouse set up, LFE provides the required expertise and experience in order to achieve the screening of local merger / acquisition candidates.

China has about 8,660 local pharmaceutical companies accredited by China GMP and 6,324 medical device manufacturers in 2011. Which provides great opportunities for foreign or local companies to achieve their strategic or operational objectives via M & A activities, i.e. acquire products, manufacturing facilities, critical mass, market access and buy out competitive threats.

M & A services we provided include but not limit to the following areas:

Screen M & A Candidates

To screen out qualified candidates in line with clients key M & A objectives. Loudon China has manufacturer and product data bases to conduct systematic screening according to product related criteria, facility related criteria, or TA revenue related criteria.

Loudon China has also build up good networks in Yangtze delta, Pearl Delta areas and other provinces, which will help to access top management of candidate companies.

Loudon China has provided M & A services for MNC life science companies of US, Europe and Japan.

Profiling M & A Candidates

Collect relevant details of corporate information, basic financials, product portfolio and pipeline, sales and distribution, manufacturing. To narrow down the list of the candidates, and priorities the candidates in terms of feasibilities and level of synergies.